Biogen

Biogen Inc. is an American multinational biotechnology company that develops and markets therapies for neurological and autoimmune diseases. Headquartered in Cambridge, Massachusetts, the company operates globally and focuses on therapies for conditions such as multiple sclerosis and spinal muscular atrophy, among others.

Biogen’s product portfolio has included Avonex (interferon beta-1a) for relapsing multiple sclerosis, Tysabri (natalizumab) for multiple sclerosis and Crohn’s disease, Tecfidera (dimethyl fumarate) for relapsing multiple sclerosis, and Spinraza (nusinersen) for spinal muscular atrophy. The company also engages in research collaborations and development programs in gene-silencing and antisense technologies to address neurological and other diseases.

History and corporate structure: Biogen was founded in 1978 as a biotechnology company. In 2003, Biogen merged with Idec Pharmaceuticals to form Biogen Idec, and in 2015 the company adopted the simplified name Biogen. It trades publicly on the NASDAQ under the ticker BIIB. The company has pursued a strategy of developing proprietary medicines alongside collaborations and acquisitions to expand its neuroscience-focused portfolio.

Research and development: Biogen concentrates its efforts on neuroscience, neurodegenerative diseases, and autoimmune disorders, with ongoing pipelines in diseases such as Alzheimer’s disease and other neurological conditions. The company also emphasizes manufacturing, quality assurance, and global distribution to support access to its therapies.

Regulatory and safety matters have shaped Biogen’s product history; for example, Tysabri was temporarily withdrawn from the market in 2005 due to safety concerns and later reintroduced with strengthened monitoring. Biogen engages with researchers, clinicians, and patient groups to advance neuroscience research and patient access to therapies.